Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754331 | 0.86 | MMP12 (0.65) | MMP12PARP1ALDH1A1MAPTKMT2A | |
| SCHEMBL861110 | 0.86 | MMP12 (0.65) | MMP12PARP1ALDH1A1MAPTKMT2A | |
| SCHEMBL6295833 | 0.83 | PDE3B (0.45) | BRD4CREBBPMMP12CYP11B1CYP11B2 | |
| SCHEMBL6296965 | 0.83 | CYP11B1 (0.44) | BRD4CREBBPMMP12CYP11B1CYP11B2 | |
| SCHEMBL6297431 | 0.83 | KIF11 (0.62) | MMP12CYP11B1CYP11B2KIF11ALDH1A1 | |
| SCHEMBL15964758 | 0.83 | MAOA (0.54) | BRD4CREBBPMMP12CYP11B1CYP11B2 | |
| SCHEMBL26604998 | 0.82 | MMP12 (0.56) | MMP12PARP1ALDH1A1MAPTKMT2A | |
| SCHEMBL1861248 | 0.79 | NR3C2 (0.57) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL304249 | 0.79 | DRD4 (0.56) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL276741 | 0.79 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PARP1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| CN-109988093-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-112442013-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022123039-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021043185-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-11 | — | — | WO | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | Trillium Therapeutics (CA) | 2019-10-01 | — | — | US | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20040224948-A1 | Novel substituted benzoxazines as integrin antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2004-11-11 | — | — | US | disclosed |
| US-6750215-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-06-15 | — | — | US | disclosed |
| US-20030073688-A1 | Novel substituted benzoxazines as integrin antagonists | POLSTER, RACHEL A. | 2003-04-17 | — | — | US | disclosed |
| EP-0237781-B1 | PHENYL AND HETEROCYCLIC TETRAHYDROPYRIDYL AND PIPERAZINYL ALKOXY-BENZHETEROCYCLIC COMPOUNDS AS ANTIPSYCHOTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4803203-A | SCHIZOPHRENIA, NEUOLEPTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-02-07 | — | — | US | disclosed |
| US-4704390-A | SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0237781-A2 | Phenyl and heterocyclic tetrahydropyridyl and piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0171702-A1 | Benzoxazinone derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885CREBBP 45/4885MMP12 1635/4885 |
| US-20040224948-A1 | Novel substituted benzoxazines as integrin antagonists | ITGB1, ITGA1, ITGB3 | BRD4 840/4885CREBBP 3060/4885MMP12 672/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885CREBBP 45/4885MMP12 1635/4885 |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | GRIN2C, ACHE, CNR1 | BRD4 1026/4885CREBBP 125/4885MMP12 2029/4885 |
| US-20030073688-A1 | Novel substituted benzoxazines as integrin antagonists | ITGB1, ITGA1, ITGB3 | BRD4 840/4885CREBBP 3060/4885MMP12 672/4885 |
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | ALDH2, ALDH1A1, ALDH3A1 | BRD4 791/4885CREBBP 606/4885MMP12 620/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | BRD4 3759/4885CREBBP 2490/4885MMP12 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.